\n<\/p>\n
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google\u2019s DeepMind<\/a> in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google\u2019s parent, it said<\/a>. \u00a0\u00a0\u00a0<\/p>\n The funding will accelerate further development of Isomorphic\u2019s AI drug design engine and support the company\u2019s goal of bringing its discovered drugs to clinical trials.<\/p>\n Isomorphic Labs was founded by DeepMind co-founder Demis Hassabis by leveraging DeepMind\u2019s software for AI drug discovery, including AlphaFold, an AI model that predicts the three-dimensional structures of proteins.<\/p>\n Last year, Isomorphic Labs secured strategic partnerships with Eli Lilly and Novartis, potentially generating up to $3 billion<\/a> in milestone payments for access to its AI model.<\/p>\n Hassabis told the New York Times<\/a> that while Isomorphic Labs didn\u2019t need the capital, the extra funding will help the division hire top research scientists.<\/p>\n For their work on AlphaFold, Hassabis and DeepMind researcher John Jumper were among the three scientists who received a Nobel Prize in chemistry<\/a> in 2024.<\/p>\n<\/div>\n